CAJ | 학술논문

目的：探讨妥洛特罗贴剂治疗C、D级COPD稳定期的有效性和安全性。方法选取2013年6月至2014年1月85例C、D级COPD稳定期患者随机分为研究组和对照组，两组均给予吸入激素、口服茶碱缓释片、痰液溶解药等综合治疗，研究组加用妥洛特罗贴剂，每日1贴（2 mg/贴）。治疗6个月。观察用药前后肺功能、临床症状评分的变化及吸入短效β2-受体激动剂的使用情况。结果两组患者治疗前肺功能指标、临床症状评分及吸入短效β2-受体激动剂的使用情况比较差异均无统计学意义（ P>0.05），治疗后两组肺功能指标、临床症状评分、吸入短效β2-受体激动剂的使用情况比较差异有统计学意义（ P<0.05）。研究组局部皮肤不良反应发生率仅2.2%，且程度轻。结论妥洛特罗贴剂能改善C、D级COPD稳定期患者的临床症状和肺功能。
목적：탐토타락특라첩제치료C、D급COPD은정기적유효성화안전성。방법선취2013년6월지2014년1월85례C、D급COPD은정기환자수궤분위연구조화대조조，량조균급여흡입격소、구복다감완석편、담액용해약등종합치료，연구조가용타락특라첩제，매일1첩（2 mg/첩）。치료6개월。관찰용약전후폐공능、림상증상평분적변화급흡입단효β2-수체격동제적사용정황。결과량조환자치료전폐공능지표、림상증상평분급흡입단효β2-수체격동제적사용정황비교차이균무통계학의의（ P>0.05），치료후량조폐공능지표、림상증상평분、흡입단효β2-수체격동제적사용정황비교차이유통계학의의（ P<0.05）。연구조국부피부불량반응발생솔부2.2%，차정도경。결론타락특라첩제능개선C、D급COPD은정기환자적림상증상화폐공능。
Objective To investigate the efficacy and safety of tulobuterol patch in treatment of C,D grade of COPD. Methods From June 2013 to January 2014,85 patients with C,D grade COPD in stable stage were randomly divided into study group and control group. The patients in the two groups were treated with inhaled corticosteroids,oral theophylline sustained-release Tablets,sputum dissolving drug therapy,and study group was given tulobuterol patch,daily 1(2 mg/paste). Treatment course was 6 months. The changes of pulmonary function,clinical symptom score and inhaled short acting β2-receptor agonists were observed before and after treatment. Results Before treatment,there was no significant difference in pulmonary function,clinical symptom score or inhaled short actingβ2-receptor agonists between the two groups(P>0. 05). After treatment,there were significant differ-ences in pulmonary function,clinical symptom score,inhaled short actingβ2-receptor agonists between the two groups(P<0. 05). The adverse reaction incidence of local skin was only 2. 2%,and the degree was light. Conclusion Tulobuterol patch can improve the clinical symptoms and pulmonary function in patients with C,D grade COPD in stable phase.